A427 Cells
General information
Description | A427 cells originate from lung tissue, specifically a carcinoma, exhibit epithelial morphology and grow adherently. A427 cells have a doubling time of approximately 28 hours in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). In ACL-3 medium, the doubling time is slightly extended to 38 hours, while in ACL-3 supplemented with bovine serum albumin (BSA), it reaches 42 hours. These variations in doubling time provide valuable insights into cell behaviour under different experimental conditions. At passage 60, A427 cells display a hypotriploid to hypertriploid karyotype. This means the cells possess abnormal chromosomes, including dicentrics, minutes, and a large subtelocentric marker. Such karyotypic abnormalities are often associated with cancer cells and contribute to the unique characteristics of this cell line. A427 cells exhibit tumorigenic properties, allowing them to form tumours when injected into nude mice. These tumours resemble undifferentiated adenocarcinoma, further emphasizing the relevance of this cell line in studying lung cancer and its progression. With its exceptional features, A427 cells find utility in various applications, particularly in cancer research. Their epithelial morphology and lung origin make them an ideal model for studying lung cancer and related diseases. Additionally, A427 cells are well-suited for 3D cell culture techniques, providing a more physiologically relevant environment to explore the behaviour of lung cancer cells. |
---|---|
Organism | Human |
Tissue | Lung |
Disease | Carcinoma |
Synonyms | A-427, A427N |
Characteristics
Age | 52 years |
---|---|
Gender | Male |
Ethnicity | Caucasian |
Morphology | Epithelial-like |
Growth properties | Adherent |
Identifiers / Biosafety / Citation
Citation | A427 (Cytion catalog number 300111) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Protein expression | p53 positive |
---|---|
Tumorigenic | Yes, in nude mice. Forms an undifferentiated tumor suggestive of adenocarcinoma. |
Karyotype | P60) hypotriploid to hypertriploid with abnormalities including dicentrics, minutes and large subtelocentric marker |
Handling
Culture Medium | EMEM, w: 2 mM L-Glutamine, w: 1.5 g/L NaHCO3, w: EBSS, w: 1 mM Sodium pyruvate, w: NEAA (Cytion article number 820100c) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:3 to 1:5 is recommended |
Seeding density | 1 x 10^4 cells/cm^2 will result in a confluent monolayer within 3 days. |
Fluid renewal | 2 to 3 times per week |
Freezing recovery | After thawing, plate the cells at 4 x 10^4 cells/cm^2 and allow the cells to recover from the freezing process and to adhere for at least 24 hours. |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,y
CSF1PO: 10,12
D13S317: 11,12
D16S539: 11,13
D5S818: 12
D7S820: 8,12
TH01: 9
TPOX: 8,11
vWA: 17
D3S1358: 16
D21S11: 32.2
D18S51: 12
Penta E: 15,17
Penta D: 13
D8S1179: 12,13
FGA: 18
|
HLA alleles |
A*: 03:01:01, 33:03:01
B*: 35:03:01
C*: 12:03:01
DRB1*: 04:08:01, 13:01:01
DQA1*: 01:03:01, 03:03:01
DQB1*: 03:04:01, 06:03:01
DPB1*: 04:01:01, 15:01:01
E: 01:01:01, 01:03
|